TABLE 3

CISA Network Key Accomplishments and Ongoing Projects

Ongoing projects
    Clinical risk assessment of new cases of GBS after immunization, including immune response and DNA studies
    Clinical risk assessment of myopericarditis after smallpox vaccination, including immune responses and DNA studies
    Retrospective Review of Safety and efficacy of live attenuated viral vaccines in patients with DiGeorge syndrome
    Ongoing registry that allows for enrollment of persons who experience an AEFI and the ability to store specimens for future studies
    Ongoing centralized immunization-safety repository of biological specimens
    Ongoing 2-year fellowship in vaccine safety
    Genetics of GBS: investigation of vaccine-associated and non–vaccine-associated GBS
    The genomics of wheezing and variable immune response after influenza vaccination in infants
    Review of immunization practices and safety among children with mitochondrial and metabolic disorders
    Acute disseminated encephalomyelitis after immunization
    Encephalitis/encephalopathy and measles-mumps-rubella vaccine
    Gelatin case-control study to evaluate immediate hypersensitivity after immunization Bell's palsy after immunizations
Key accomplishments
    Developed an evidenced-based algorithm for managing individuals with vaccine hypersensitivity reaction following vaccination2
    Developed and evaluated an algorithm for assessing causality in the evaluation of AEFI5
    Evaluated adverse reactions after the fifth dose of DTaP25
    Assessed the role for genetics in the immune response to the varicella vaccine9
    Evaluated adverse events among civilian smallpox vaccine recipients via telephone surveillance6
    Evaluated cases of viscerotropic and neurotropic illness after yellow fever vaccine26
    Determined via case-control study of SV40 and non-Hodgkin lymphoma that past infection with SV40 is not associated with increased risk of developing non-Hodgkin lymphoma27
    Evaluated risk factors for developing apnea after immunization in the NICU23
    Studied immunogenicity and safety of vaccines administered to premature infants24
    Evaluated AEFI after yellow fever vaccine via active surveillance28
    Studied Vaccine Acceptance & Risk Perception22
    Studied alopecia associated with hepatitis B vaccination by using a mouse model29
    Evaluated immunization rates and safety among children with inborn errors of metabolism30
    Evaluated hyperammonemic events are not associated with a 21-d postvaccination window in 90 children with urea cycle disorders31
  • GBS indicates Guillain-Barré Syndrome; IRB, institutional review board; SV40, simian virus 40; DTaP, diphtheria-tetanus-acellular pertussis.